Zoetis Inc. announced on February 14, 2025, that its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, received a conditional license from the U.S. Department of Agriculture (USDA) for use in poultry. This approval is based on demonstrated safety, purity, and reasonable expectation of efficacy.
The conditional license is granted to address emergency conditions, limited markets, or special circumstances, and is issued for a finite period. This development positions Zoetis to support poultry producers in managing Highly Pathogenic Avian Influenza (HPAI), which has affected over 150 million birds in the U.S. since February 2022.
Mahesh Kumar, Ph.D., Senior Vice President, Global Biologics Research and Development at Zoetis, stated that the company's scientists immediately began updating their previous avian influenza vaccine when a new HPAI strain was identified in early 2022. This vaccine is a solution to global animal health challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.